Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.

TitleImmunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
Publication TypeJournal Article
Year of Publication2020
AuthorsPareja F, da Silva EM, Frosina D, Geyer FC, Lozada JR, Basili T, Paula ADa Cruz, Zhong E, Derakhshan F, D'Alfonso T, Wen HY, Giri DD, Hayes MM, Krings G, Bhargava R, Palazzo JP, Rakha EA, Hoda SA, Sanders ME, Collins LC, Schnitt SJ, Chen Y-Y, Weigelt B, Jungbluth AA, Reis-Filho JS, Brogi E
JournalMod Pathol
Volume33
Issue6
Pagination1056-1064
Date Published2020 06
ISSN1530-0285
KeywordsAged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, Carcinoma, Papillary, Cell Polarity, Female, Humans, Immunohistochemistry, Isocitrate Dehydrogenase, Middle Aged, Mutation
Abstract

Tall cell carcinoma with reverse polarity is a rare subtype of breast carcinoma with solid and papillary growth and nuclear features reminiscent of those of the tall cell variant of papillary thyroid carcinoma. These tumors harbor recurrent IDH2 R172 hotspot mutations or TET2 mutations, co-occurring with mutations in PI3K pathway genes. Diagnosis of tall cell carcinomas with reverse polarity is challenging in view of their rarity and the range of differential diagnosis. We sought to determine the sensitivity and specificity of IDH2 R172 immunohistochemistry for the detection of IDH2 R172 hotspot mutations in this entity. We evaluated 14 tall cell carcinomas with reverse polarity (ten excision and five core needle biopsy specimens), 13 intraductal papillomas, 16 solid papillary carcinomas, and 5 encapsulated papillary carcinomas by Sanger sequencing of the IDH2 R172 hotspot locus and of exons 9 and 20 of PIK3CA, and by immunohistochemistry using monoclonal antibodies (11C8B1) to the IDH2 R172S mutation. The 14 tall cell carcinomas with reverse polarity studied harbored IDH2 R172 hotspot mutations, which co-occurred with PIK3CA hotspot mutations in 50% of cases. None of the other papillary neoplasms analyzed displayed IDH2 R172 mutations, however PIK3CA hotspot mutations were detected in 54% of intraductal papillomas, 6% of solid papillary carcinomas, and 20% of encapsulated papillary carcinomas tested. Immunohistochemical analysis with anti-IDH2 R172S antibodies (11C8B1) detected IDH2 R172 mutated protein in 93% (14/15) of tall cell carcinomas with reverse polarity samples including excision (n = 9/10) and core needle biopsy specimens (n = 5), whereas the remaining papillary neoplasms (n = 34) were negative. Our findings demonstrate that immunohistochemical analysis of IDH2 R172 is highly sensitive and specific for the detection of IDH2 R172 hotspot mutations, and likely suitable as a diagnostic tool in the evaluation of excision and core needle biopsy material of tall cell carcinomas with reverse polarity.

DOI10.1038/s41379-019-0442-2
Alternate JournalMod Pathol
PubMed ID31896809
PubMed Central IDPMC7286791
Grant ListK12 CA184746 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
Related Faculty: 
Syed Hoda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700